Description
Vaccines can be made against KSHV by generating a protein with the central repeat domain deleted. These antigens will have enhanced immunogenicity against the remaining N-terminal and C-terminal peptides. Alternatively, the central repeat domain can be cloned as a fusion protein into a gene delivery vector. Expression of the central repeat domain will increase protein stabilization and decrease immunogenicity of the transgenic protein. The LANA1 repeat domain may be a useful and simple means to increase gene therapy delivered protein expression.
IP Status
https://patents.google.com/patent/US10022438B2
